Document:

Exhibit 4.5

 

Description
of Securities of NeuBase Therapeutics, Inc.

 

The authorized capital stock of NeuBase Therapeutics, Inc. (the
 “Company”) consists of:

 

		·	250,000,000 shares of common stock, $0.0001 par value (“Common Stock”); and

		·	10,000,000 shares of preferred stock, $0.0001 par value (“Preferred Stock”).

 

Common Stock

 

Except as otherwise expressly provided in the Company’s
Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), or as required
by applicable law, all shares of the Company’s Common Stock have the same rights and privileges and rank equally, share ratably
and are identical in all respects as to all matters, including, without limitation, those described below:

 

		·	Voting rights. Each holder of Common Stock is entitled to one vote per share for the election of directors and
on all other matters that require stockholder approval. Holders of Common Stock do not have any cumulative voting rights. As further
described below in the section titled “Anti-Takeover Effects of Provisions of the Company’s Certificate of Incorporation
and Delaware Law – Classified Board; Election and Removal of Directors; Filling Vacancies”, the Certificate of Incorporation
and the Company’s Amended and Restated Bylaws, as amended (the “Bylaws”), provide for a classified board of directors
consisting of three classes of approximately equal size, each serving staggered three-year terms. There is no provision for cumulative
voting for the election of directors, which means that a plurality of the shares voted can elect all of the directors then standing
for election. Except as provided under the General Corporation Law of the State of Delaware (“DGCL”) or the Certificate
of Incorporation and the Bylaws, action on a matter is approved if the votes cast favoring the action exceed the votes cast opposing
the action.

		·	Dividend rights. The holders of outstanding shares of Common Stock are entitled to receive dividends out of funds
legally available if the Company’s board of directors, in its discretion, determines to issue dividends and only at the times
and in the amounts that the Company’s board of directors may determine and will depend upon the Company’s earnings,
if any, capital requirements, operating and financial conditions and on such other factors as the Company’s board of directors
deems relevant.

		·	Liquidation rights. Upon the Company’s liquidation, dissolution or winding-up, the holders of Common Stock
will be entitled to share equally, identically and ratably in all assets remaining, subject to the prior satisfaction of all outstanding
debt and liabilities and the preferential rights and payment of liquidation preferences, if any, on any outstanding shares of Preferred
Stock.

		·	No preemptive or similar rights. The Common Stock does not carry any redemption rights or any preemptive or preferential
rights enabling a holder to subscribe for, or receive shares of, any class of Common Stock or any other securities convertible
into shares of any class of Common Stock. The Common Stock is not subject to conversion, redemption or sinking fund provisions.

		·	Anti-Takeover Provisions. The section below titled “Anti-Takeover Effects of Provisions of the Company’s
Certificate of Incorporation and Delaware Law” is incorporated herein by reference.

 

    

     

    

 

Listing

 

The Company’s Common Stock is listed on the Nasdaq Capital
Market under the symbol “NBSE”.

 

Preferred Stock

 

Under the Certificate of Incorporation, the Company’s
board of directors has the authority, without further action by stockholders, to designate one or more series of Preferred Stock
and to fix the voting powers, designations, preferences, limitations, restrictions and relative rights granted to or imposed upon
the Preferred Stock, including dividend rights, conversion rights, voting rights, rights and terms of redemption, liquidation preference
and sinking fund terms, any or all of which may be preferential to or greater than the rights of the Company’s Common Stock.

 

The Company’s board of directors may authorize the issuance
of Preferred Stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders
of Common Stock. The issuance of Preferred Stock, while providing flexibility in connection with possible acquisitions and other
corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control and may
adversely affect the market price of the Common Stock and the voting and other rights of the holders of Common Stock.

 

The Company’s board of directors may specify the following
characteristics of any Preferred Stock:

 

		·	the designation and stated value, if any, of the class or series of Preferred Stock;

		·	the number of shares of the class or series of Preferred Stock offered, and the liquidation preference, if any, per share;

		·	the dividend rate(s), period(s) or payment date(s) or method(s) of calculation, if any, applicable to the class or series of
Preferred Stock;

		·	whether dividends, if any, are cumulative or non-cumulative and, if cumulative, the date from which dividends on the class
or series of Preferred Stock will accumulate;

		·	the provisions for a sinking fund, if any, for the class or series of Preferred Stock;

		·	the provision for redemption, if applicable, of the class or series of Preferred Stock;

		·	the terms and conditions, if applicable, upon which the class or series of Preferred Stock will be convertible into Common
Stock, including the conversion price or manner of calculation and conversion period;

		·	voting rights, if any, of the class or series of Preferred Stock;

		·	the relative ranking and preferences of the class or series of Preferred Stock as to dividend rights and rights, if any, upon
the liquidation, dissolution or winding up of our affairs;

		·	any limitations on issuance of any class or series of Preferred Stock ranking senior to or on a parity with the class or series
of Preferred Stock as to dividend rights and rights, if any, upon liquidation, dissolution or winding up of our affairs; and

		·	any other specific terms, preferences, rights, limitations or restrictions of the class or series of Preferred Stock.

 

    

     

    

 

Warrants

 

December 2016 Warrants

 

On December 7, 2016, the Company entered into a securities purchase
agreement with the purchasers set forth on the signature pages thereto, pursuant to which the Company agreed to issue and sell
Series A Warrants to purchase shares of Common Stock (the “December 2016 Warrants”). On December 13, 2016, the Company
issued the December 2016 Warrants.

 

As of September 30, 2019, December 2016 Warrants to purchase
20,627 shares of Common Stock were outstanding and exercisable.

 

Exercisability. The December 2016 Warrants were immediately
exercisable upon issuance and will expire on December 13, 2021.

 

The December 2016 Warrants are exercisable, at the option of
each holder, in whole or in part by delivering to the Company a duly executed exercise notice and by payment in full in immediately
available funds for the number of shares of Common Stock purchased upon such exercise. If a registration statement registering
the issuance of the shares of Common Stock underlying December 2016 Warrants under the Securities Act of 1933, as amended (the
 “Securities Act”), is not then effective or available, the holder may exercise the December 2016 Warrant through a
cashless exercise, in whole or in part, in which case the holder would receive upon such exercise the net number of shares of Common
Stock determined according to the formula set forth in the December 2016 Warrant. No fractional shares of Common Stock will be
issued in connection with the exercise of a December 2016 Warrant. In lieu of fractional shares, the Company will either pay the
holder an amount in cash equal to the fractional amount multiplied by the exercise price or round up to the next whole share.

 

Exercise Limitation. A holder will not have the right
to exercise any portion of a December 2016 Warrant if the holder (together with its affiliates) would beneficially own in excess
of 4.99% (or on election of the holder, 9.99%) of the number of shares of the Company’s Common Stock outstanding immediately
after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the December 2016
Warrants. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided
that any increase in such percentage shall not be effective until 61 days after such notice to us.

 

Exercise Price. The exercise price per share of Common
Stock purchasable upon exercise of one December 2016 Warrant is $55.00 per share of Common Stock. The exercise price is subject
to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications
or similar events affecting the Company’s Common Stock.

 

Transferability. Subject to applicable laws, the December
2016 Warrants may be offered for sale, sold, transferred or assigned without the Company’s consent. There is currently no
trading market for the December 2016 Warrants and a trading market is not expected to develop.

 

Exchange Listing. The December 2016 Warrants are not
listed on the Nasdaq Capital Market, any other national securities exchange or any other nationally recognized trading system.

 

    

     

    

 

Fundamental Transactions. In the event of a fundamental
transaction, the holders of the December 2016 Warrants will be entitled to receive upon exercise of the December 2016 Warrants
the kind and amount of securities with cash or other property that the holders would have received had they exercised the December
2016 Warrants immediately prior to such fundamental transaction. At the holder’s election, exercisable at any time concurrently
with, or within 30 days after, the consummation of a fundamental transaction, the Company or any successor entity shall purchase
the December 2016 Warrants from the holder by paying the holder an amount of cash equal to the Black-Scholes Value.

 

A “fundamental transaction” means any of the following:
(i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company
with or into another person; (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer,
conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions; (iii) any,
direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another person) is completed pursuant
to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property
and has been accepted by the holders of 50% or more of the outstanding Common Stock; (iv) the Company, directly or indirectly,
in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any
compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash
or property; or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase
agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme
of arrangement) with another person or group of persons whereby such other person or group acquires more than 50% of the outstanding
shares of Common Stock (not including any shares of Common Stock held by the other person or other persons making or party to,
or associated or affiliated with the other persons making or party to, such stock or share purchase agreement or other business
combination).

 

“Black-Scholes Value” means the value of a December
2016 Warrant based on the Black and Scholes Option Pricing Model obtained from the “OV” function on Bloomberg, L.P.
(“Bloomberg”) determined as of the day of consummation of the applicable fundamental transaction for pricing purposes
and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the
date of the public announcement of the applicable fundamental transaction and December 13, 2021, (B) an expected volatility equal
to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg as of the trading day immediately
following the public announcement of the applicable fundamental transaction, (C) the underlying price per share used in such calculation
shall be the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being
offered in such fundamental transaction, and (D) a remaining option time equal to the time between the date of the public announcement
of the applicable fundamental transaction and December 13, 2021.

 

Rights as a Stockholder. Except as otherwise provided
in the December 2016 Warrants or by virtue of such holder’s ownership of shares of the Company’s Common Stock, the
holder of a December 2016 Warrant does not have the rights or privileges of a holder of Common Stock, including any voting rights,
until the holder exercises the December 2016 Warrant.

 

    

     

    

 

April 2017 Warrants

 

On April 5, 2017, the Company entered into a securities purchase
agreement with the purchasers set forth on the signature pages thereto, pursuant to which the Company agreed to issue and sell
warrants to purchase shares of Common Stock (the “April 2017 Warrants”). On April 10, 2017, the Company issued the
April 2017 Warrants.

 

As of September 30, 2019, April 2017 Warrants to purchase 695,312
shares of Common Stock were outstanding and exercisable.

 

Exercisability. The April 2017 Warrants were immediately
exercisable upon issuance and will expire on April 10, 2017.

 

The April 2017 Warrants are exercisable, at the option of each
holder, in whole or in part by delivering to the Company a duly executed exercise notice and by payment in full in immediately
available funds for the number of shares of Common Stock purchased upon such exercise. Following the one year anniversary of the
date the April 2017 Warrants are issued, the holder may exercise the April 2017 Warrants through a cashless exercise, in whole
or in part, in which case the holder would receive upon such exercise the net number of shares of Common Stock determined according
to the formula set forth in the warrant. No fractional shares of Common Stock will be issued in connection with the exercise of
an April 2017 Warrant. In lieu of fractional shares, the Company will either pay the holder an amount in cash equal to the fractional
amount multiplied by the exercise price or round up to the next whole share.

 

Exercise Limitation. A holder will not have the right
to exercise any portion of the April 2017 Warrant if the holder (together with its affiliates) would beneficially own in excess
of 4.99% (or on election of the holder, 9.99%) of the number of shares of the Company’s Common Stock outstanding immediately
after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the April 2017
Warrants. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided
that any increase in such percentage shall not be effective until 61 days after such notice to the Company.

 

Exercise Price. The initial exercise price per share
of Common Stock purchasable upon exercise of one April 2017 Warrant is $20.00 per share of Common Stock. The exercise price
is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations,
reclassifications or similar events affecting the Company’s Common Stock.

 

Transferability. Subject to applicable laws, the April
2017 Warrants may be offered for sale, sold, transferred or assigned without the Company’s consent. There is currently no
trading market for the April 2017 Warrants and a trading market is not expected to develop.

 

Exchange Listing. The April 2017 Warrants are not listed
on the Nasdaq Capital Market, any other national securities exchange or any other nationally recognized trading system.

 

Fundamental Transactions. In the event of a fundamental
transaction, the holders of the April 2017 Warrants will be entitled to receive upon exercise of the April 2017 Warrants the kind
and amount of securities with cash or other property that the holders would have received had they exercised the April 2017 Warrants
immediately prior to such fundamental transaction.

 

    

     

    

 

A “fundamental transaction” means any of the following:
(i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company
with or into another person; (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer,
conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions; (iii) any,
direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another person) is completed pursuant
to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property
and has been accepted by the holders of 50% or more of the outstanding Common Stock; (iv) the Company, directly or indirectly,
in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any
compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash
or property; or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase
agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme
of arrangement) with another person or group of persons whereby such other person or group acquires more than 50% of the outstanding
shares of Common Stock (not including any shares of Common Stock held by the other person or other persons making or party to,
or associated or affiliated with the other persons making or party to, such stock or share purchase agreement or other business
combination).

 

Rights as a Stockholder. Except as otherwise provided
in the April 2017 Warrants or by virtue of such holder’s ownership of shares of the Company’s Common Stock, the holder
of a April 2017 Warrants does not have the rights or privileges of a holder of Common Stock, including any voting rights, until
the holder exercises the April 2017 Warrant.

 

Anti-Takeover Effects of Provisions of the Company’s
Certificate of Incorporation and Delaware Law

 

Certain provisions of Delaware law and the Certificate of Incorporation
contain provisions that could make the following transactions more difficult: acquisition of the Company by means of a tender offer;
acquisition of the Company by means of a proxy contest or otherwise; or removal of the Company’s incumbent officers and directors.
It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may
otherwise consider to be in their best interest or in the Company’s best interests, including transactions that might result
in a premium over the market price for the Company’s capital stock.

 

These provisions, summarized below, are expected to discourage
coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire
control of the Company to first negotiate with the Company’s board of directors. The Company believes that the benefits of
increased protection of the Company’s potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal
to acquire or restructure the Company outweigh the disadvantages of discouraging these proposals because negotiation of these proposals
could result in an improvement of their terms.

 

    

     

    

 

Delaware Anti-Takeover Statute

 

The Company is subject to Section 203 of the DGCL, which prohibits
persons deemed “interested stockholders” from engaging in a “business combination” with a publicly-held
Delaware corporation for three years following the date these persons become interested stockholders unless the business combination
is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed
exception applies. Generally, an “interested stockholder” is a person who, together with affiliates and associates,
owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation’s
voting stock. Generally, a “business combination” includes a merger, asset or stock sale, or other transaction resulting
in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect
to transactions not approved in advance by the board of directors, such as discouraging takeover attempts that might result in
a premium over the market price of the Common Stock.

 

Undesignated Preferred Stock

 

The ability to authorize undesignated Preferred Stock will make
it possible for the Company’s board of directors to issue Preferred Stock with voting or other rights or preferences that
could impede the success of any attempt to change control of the Company. These and other provisions may have the effect of deterring
hostile takeovers or delaying changes in control or management of the Company.

 

Elimination of Stockholder Action by Written Consent

 

The Certificate of Incorporation eliminates the right of stockholders
to act by written consent without a meeting.

 

Classified Board; Election and Removal of Directors; Filling
Vacancies

 

The Company’s board of directors is divided into three
classes. The directors in each class serve for a three-year term, one class being elected each year by the Company’s stockholders,
with staggered three-year terms. Only one class of directors will be elected at each annual meeting of the Company’s stockholders,
with the other classes continuing for the remainder of their respective three-year terms. At all meetings of stockholders for the
election of directors, a plurality of the votes cast is sufficient to elect each director. The Certificate of Incorporation provides
for the removal of any of the Company’s directors only for cause and requires a stockholder vote by the holders of at least
66 2/3% of the voting power of the then outstanding voting stock with the power to vote at an election of directors. Furthermore,
any vacancy on the Company’s board of directors, however occurring, including a vacancy resulting from an increase in the
size of the board, shall only be filled by a resolution of the board of directors unless the board of directors determines that
such vacancies shall be filled by the stockholders. This system of electing and removing directors and filling vacancies may tend
to discourage a third party from making a tender offer or otherwise attempting to obtain control of the Company, because it generally
makes it more difficult for stockholders to replace a majority of the directors.

 

    

     

    

 

Choice of Forum

 

The Certificate of Incorporation provides that, unless the Company
consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the exclusive
forum for: (a) any derivative action or proceeding brought on the Company’s behalf; (b) any action asserting a claim of breach
of fiduciary duty owed by any director, officer, employee, agent or stockholder of the Company to the Company or the Company’s
stockholders, creditors or other constituents; (c) any action asserting a claim against the Company arising pursuant to the DGCL,
the Certificate of Incorporation or the Bylaws; or (d) any action asserting a claim governed by the internal affairs doctrine.
Such exclusive forum provision, however, does not apply to suits brought to enforce any liability or duty created by the Securities
Act or the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or any other claim for which the federal
courts have exclusive jurisdiction. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought
to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. As a result, the choice of
forum provision will not apply to suits brought to enforce any duty or liability created by the Exchange Act or any other claim
for which the federal courts have exclusive jurisdiction. It could apply, however, to a suit that falls within one or more of the
categories enumerated in the choice of forum provision and asserts claims under the Securities Act inasmuch as Section 22 of the
Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability
created by the Securities Act or the rules and regulations thereunder. There is uncertainty as to whether a court would enforce
this provision with respect to claims under the Securities Act.

 

However, the Certificate of Incorporation does not relieve the
Company of its duty to comply with federal securities laws and the rules and regulations thereunder, and the Company’s stockholders
will not be deemed to have waived the Company’s compliance with these laws, rules and regulations. The Certificate of Incorporation
also provide that any person or entity purchasing or otherwise acquiring any interest in shares of the Company’s capital
stock will be deemed to have notice of and consented to this choice of forum provision.

 

This choice of forum provision in the Certificate of Incorporation
may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with the Company
or its directors, officers or other employees, which may discourage such lawsuits against the Company and its directors, officers
and other employees. In addition, stockholders who do bring a claim in the Court of Chancery in the State of Delaware could face
additional litigation costs in pursuing any such claim, particularly if they do not reside in or near Delaware. Furthermore, the
enforceability of similar choice of forum provisions in other companies’ governing documents has been challenged in legal
proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable.

 

Amendment of Charter Provisions

 

The amendment of any of the above provisions in the Certificate
of Incorporation, except for the provision making it possible for the Company’s board of directors to issue undesignated
Preferred Stock, would require approval by a stockholder vote by the holders of at least 66 2/3% of the voting power of the then
outstanding voting stock.

 

The provisions of the DGCL and the Certificate of Incorporation
could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary
fluctuations in the market price of the Common Stock that often result from actual or rumored hostile takeover attempts. These
provisions may also have the effect of preventing changes in the Company’s management. It is possible that these provisions
could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests.Exhibit 10.29

 

Sublease Agreement

 

This Commercial Sublease (this “Sublease”) is made
effective as of March 12, 2019, by and between StartUptown dba Avenu (“Tenant”), and NeuBase Therapeutics Inc.
(“Subtenant”). Tenant has previously entered into a lease agreement with Carnegie Mellon University (“Landlord”)
dated March 12, 2019 (the “Prime Lease”), a copy of which is attached as an exhibit to this Sublease. Tenant now
desires to sublet the leased property to Subtenant and Subtenant desires to sublet the leased property from Tenant. Therefore,
the parties agree as follows:

 

PREMISES. Tenant, in consideration of the sublease payments
provided in this Agreement, sublets to Subtenant 880 rentable square feet, identified as such laboratory and office space
listed in Exhibit A attached hereto, located on the third floor of 700 Technology Drive, Pittsburgh, Pennsylvania 15219
(the “Premises”) and known as Landlord’s Pittsburgh, Pennsylvania, university campus as the Pittsburgh Technology
Center.

 

TERM AND POSSESSION. Subtenant will sublease the Premises
for a term commencing on April 1, 2019 (the “Commencement Date”) and ending one (1) year from the Commencement
Date (the “Initial Sublease Term”), or at Subtenant’s one-time option, for an additional period of up to six
(6) successive months following the completion of the Initial Sublease Term (the “Extended Sublease Term”), provided
that Subtenant has given Tenant written notice of its intention to exercise such option at least three (3) months prior to
the end of the Initial Sublease Term and, if the said written notice has been provided by Subtenant in accordance with the foregoing.

 

SUBLEASE PAYMENTS. Subtenant shall pay to Tenant sublease
payments of 2,531.73 per month, payable in advance on the first day of each month, for a total sublease payment of 30,380.76.
Sublease payments shall be made to Tenant at c/o InnovatePGH, 3710 Forbes Avenue, 2nd Floor, Pittsburgh, Pennsylvania 15213,
which may be changed from time to time by Tenant.

 

Subtenant shall pay for all utilities used or consumed at the
Demised Premises during the term of this Agreement as currently obligated by the Tenant under the Prime Lease. The utilities shall
be paid directly to the utility company if separately metered; otherwise, the utilities shall be prorated by Tenant in a fair and
equitable manner as mutually agreed to by Tenant and Subtenant and be billed to Subtenant at the same rates as billed to Tenant
by the utility company for payment to Tenant. The bills shall be due and payable within ten days of receipt.

 

DEFAULTS. Subtenant shall be in default of this
Sublease if Subtenant fails to fulfill any lease obligation or term by which Subtenant is bound. Subject to any governing
provisions of law to the contrary, if Subtenant fails to cure any financial obligation within 5 days (or any other
obligation within 10 days) after written notice of such default is provided by Landlord to Subtenant, Landlord may
take possession of the Premises without further notice (to the extent permitted by law), and without prejudicing
Landlord’s rights to damages. In the alternative, Landlord may elect to cure any default and the cost of such action
shall be added to Subtenant’s financial obligations under this Sublease. Subtenant shall pay all costs, damages, and
expenses (including reasonable attorney fees and expenses) suffered by Landlord by reason of Subtenant’s defaults. All
sums of money or charges required to be paid by Subtenant under this Sublease shall be additional rent, whether or not such
sums or charges are designated as “additional rent”. The rights provided by this paragraph are cumulative in
nature and are in addition to any other rights afforded by law.

 

     

     

    

 

SECURITY DEPOSIT. At the time of the signing of this
Sublease, Subtenant shall pay to Landlord, in trust, a security deposit of 2,531.73 to be held and disbursed for Subtenant
damages to the Premises or other defaults under this Sublease (if any) as provided by law.

 

CUMULATIVE RIGHTS. The rights of the parties under this
Sublease are cumulative, and shall not be construed as exclusive unless otherwise required by law.

 

NON-SUFFICIENT FUNDS. Subtenant shall be charged $35.00
for each check that is returned to Landlord for lack of sufficient funds.

 

INSURANCE. Subtenant shall procure and maintain during
the term, at its own expense, the following types of insurance with limits of liability shown below with insurance carriers that
have an A.M. Best rating of at least an “A-” or similar rating and that are acceptable to Landlord and Tenant:

 

	(i) Commercial General Liability— But not limited to, products, contractual, completed operations, personal injury, and medical payments;	$2,000,000 General Aggregate

$2,000,000 Products-Completed/Operations

$2,000,000 Personal & Adv.  Inj.

$2,000,000 Each Occurrence

$100,000 Fire Damage Limit

$10,000 Medical Expense
	(ii) Automobile Liability, including for all owned, hired car and non-owned autos;	$1,000,000 Per Accident
	(iii) Workers’ Compensation	Statutory
	and Employer’s Liability	$1,000,000 Each Accident

$1,000,000 Disease–Policy Limit

$1,000,000 Disease–Each Employee
	(iv) Excess/Umbrella Liability	$4,000,000 Occurrence/Aggregate

 

Subtenant agrees to name Tenant and Landlord as an additional
insured on policies listed above as items (i), (ii) and (iv). If Subtenant fails to maintain such insurance as described above,
Landlord or Tenant shall have the right, but not the obligation, to purchase such insurance at Subtenant’s expense.

 

Subtenant agrees to apply its insurance or self-insurance on
a “primary” basis with respect to any and all insurance coverages that Landlord may have.

 

     

     

    

 

Subtenant shall send/fax to Landlord and Tenant one (1) current
Certificate of Insurance, appropriately identified with the address of the Building and Premises in connection with the execution
of this Lease to the address set forth below, and thereafter, upon renewal of the required insurance policies.

 

WAIVER OF RIGHTS. Each of Tenant and Subtenant agrees
to, and does hereby, waive all rights of recovery and causes of action against the other, their respective agents and employees,
and all persons claiming through or under the other, relating to loss of business, business interruption or loss of rentals resulting
from any damage or destruction to the Demised Premises or any of Subtenant’s property contained therein, notwithstanding
that any such damage or destruction may be due to the negligence of Tenant or Subtenant, their respective agents or employees.
Tenant and Subtenant also waive all rights of recovery and causes of action against Lessor for loss of business, business interruption
or loss of rentals, resulting from any such damage or destruction, notwithstanding that such damage or destruction may be due to
the negligence of Tenant or Subtenant, their respective agents and employees.

 

NOTICE. Notices under this Sublease shall not be deemed
valid unless given or served in writing and forwarded by mail, postage prepaid, addressed as follows to every interested party:

 

TENANT:

 

StartUptown dba Avenu

544 Miltenberger Street

Pittsburgh, Pennsylvania 15219

 

SUBTENANT:

 

NeuBase Therapeutics Inc.

213 Smithfield Street

Pittsburgh, Pennsylvania 15222

 

LANDLORD:

 

Carnegie Mellon University

5000 Forbes Avenue

Pittsburgh, Pennsylvania 15213

 

Such addresses may be changed from time to time by any party
by providing notice to the other interested parties as described above.

 

GOVERNING LAW. This Sublease shall be construed in accordance
with the laws of the Commonwealth of Pennsylvania.

 

LANDLORD’S CONSENT. The Prime Lease requires the
prior written consent of Landlord to any subletting of the Premises.

 

     

     

    

 

INCORPORATION OF PRIME LEASE. This Sublease is
subject to all of the terms of the Prime Lease with the same force and effect as if each provision of the Prime Lease were
included in this Sublease, except as otherwise provided in this Sublease. All of the obligations and rights of Tenant under
the Prime Lease shall be binding upon Subtenant. All of the obligations of Landlord under the Prime Lease shall inure to the
benefit of Subtenant. It is the intent of the parties that, except as otherwise provided in this Sublease, the relationship
between Tenant and Subtenant shall be governed by the various provisions of the Prime Lease as if those provisions were
included in this Sublease in full, except that the terms “Landlord,” “Tenant” and “Lease”
as used in the Prime Lease, shall instead refer to, respectively, “Tenant,” “Subtenant” and
 “Sublease.” The Subtenant herein executes this Sublease with the express acknowledgement that Subtenant has read,
reviewed, understands and agrees to comply with all obligations, rights, limitation and responsibilities contained in the
Prime Lease.

 

	TENANT	 
	 	 
	/s/ Sean C. Luther	 
	StartUptown dba Avenu	 
	by: Sean C. Luther	 
	Executive Director	 

 

 

	SUBTENANT	 
	 	 
	/s/ Dr. Dietrich Stephan	 
	NeuBase Therapeutics Inc.	 
	by: Dr. Dietrich Stephan	 

 

     

     

    

 

EXHIBIT A

 

DESCRIPTION OF PREMISES

 

Certain suites located on the 3rd floor the
Pittsburgh Technology Center, 700 Technology Drive, Pittsburgh, PA 15213, designated as: Room 3316 comprised of 621
SF and Room 3321 comprised of 187 SF.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}]]